ArticleInfection and drug resistance2020
Evaluation of Resistance Mechanisms in Carbapenem-Resistant
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis.Antimicrobial agents and chemotherapy · 2026Pooled it
- Extended-spectrum β-lactamase production and antimicrobial resistance among Enterobacteriaceae causing clinical infections in Africa: a systematic review and meta-analysis (2012-2020).European journal of medical research · 2025Pooled it
- Proteome Remodeling of a Carbapenem-Resistant Escherichia coli Strain upon Meropenem Exposure.Journal of proteome research · 2026Article
- Trends in Enterobacteriaceae Resistance Patterns: A Nine-Year Retrospective Study From North Lebanon.Health science reports · 2026Article
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
- Epidemiology and clinical outcomes of carbapenamase-producing organism (CPO) colonization: a tertiary care center experience in Saudi Arabia.BMC infectious diseases · 2026Article
- Emerging reservoirs of metallo-β-lactamase genes among non-Frontiers in microbiology · 2026Article
- Clinical carbapenem-resistantMicrobiology spectrum · 2025Article
- Detection and characterization of multidrug-resistantVeterinary world · 2025Article
- Phenotypic, Targeted Genotypic, and Antimicrobial Susceptibility Profiling of Extended-Spectrum β-Lactamase Production and Exclusive blaJournal of clinical laboratory analysis · 2025Article
- Metallo Beta Lactamase Enzymes.Indian journal of microbiology · 2025Review
- Analysis of rectal carbapenem-resistant Enterobactericeae colonization results first report in Istanbul/Turkiye: Klebsiella pneumoniae co-producing blaBMC infectious diseases · 2025Article
- Risk Factors for Non-Carbapenemase-Producing Carbapenem-ResistantGeriatrics (Basel, Switzerland) · 2025Article
- Phenotypic and in silico characterization of carbapenem-resistant Serratia marcescens clinical strains.Journal of global antimicrobial resistance · 2025Article
- A retrospective study of the antimicrobial susceptibility patterns ofFrontiers in microbiology · 2025Article
- Epidemiology and resistance mechanisms of tigecycline- and carbapenem-resistantFrontiers in microbiology · 2025Article
- Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016-2020.Antibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Resistance in Bacteria from Meat and Meat Products: A One Health Perspective.Microorganisms · 2023Review
- Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.The Journal of antimicrobial chemotherapy · 2023Article
- High Frequency ofInfection & chemotherapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant
aimThis study aimed to investigate the resistance mechanisms of CRE by phenotypic and molecular methods. MATERIALS AND
methodsSixty CRE (50
resultsSixty CRE (50
conclusionThe amikacin is considered as a very efficient antibiotic for the treatment of CRE isolates in our region. Carbapenemase production and overproduction of AmpC are the main carbapenem resistance mechanisms in CRE isolates. Finally, Carba NP test is a rapid and reliable test for early detection of carbapenemase-producing isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.